Tags : Non-Metastatic

Astellas’ Xtandi (enzalutamide) Receives EU’s Approval for Men with High-Risk

Vartika Singh October 30, 2018

Shots: The EU approval is based on results of P-III PROSPER trial assessing Xtandi+ ADT vs. PBO + ADT in patients with nmCRPC and PSA level The P-III PROSPER trial […]readmore

Tags : Non-Metastatic

Astellas’ Xtandi (enzalutamide) Receives EU’s Approval for Men with High-Risk

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Non-Metastatic

Astellas’ Xtandi (enzalutamide) Receives EU’s Approval for Men with High-Risk

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company